CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-10-08 | MOORE ALISON Chief Technical Officer | Option exercise | +5,065 | $2.27 | $11K | 122,745 |
| 2020-10-08 | MOORE ALISON Chief Technical Officer | Sale | −5,065 | $41.00 | $208K | 117,680 |
| 2020-10-08 | MOORE ALISON Chief Technical Officer | Option exercise · Stock Option (Right to Buy) | −5,065 | 645,422 | ||
| 2020-10-07 | Amado Rafael EVP of R&D and CMO | Sale | −16,538 | $39.40 | $652K | 111,677 |
| 2020-10-06 | MOORE ALISON Chief Technical Officer | Option exercise | +35,264 | $2.27 | $80K | 161,536 |
| 2020-10-06 | MOORE ALISON Chief Technical Officer | Sale | −44,574 | $40.00 | $1.8M | 117,680 |
| 2020-10-06 | MOORE ALISON Chief Technical Officer | Option exercise · Stock Option (Right to Buy) | −35,264 | 650,487 | ||
| 2020-10-06 | Bhavnagri Veer General Counsel | Option exercise | +10,000 | $2.27 | $23K | 363,902 |
| 2020-10-06 | Bhavnagri Veer General Counsel | Sale | −10,000 | $40.00 | $400K | 353,902 |
| 2020-10-06 | Bhavnagri Veer General Counsel | Option exercise · Stock Option (Right to Buy) | −10,000 | 213,800 | ||
| 2020-10-01 | Bhavnagri Veer General Counsel | Option exercise | +25,000 | $2.27 | $57K | 378,902 |
| 2020-10-01 | Bhavnagri Veer General Counsel | Sale | −16,215 | $36.21 | $587K | 362,687 |
| 2020-10-01 | Bhavnagri Veer General Counsel | Sale | −7,985 | $37.03 | $296K | 354,702 |
| 2020-10-01 | Bhavnagri Veer General Counsel | Sale | −800 | $37.73 | $30K | 353,902 |
| 2020-10-01 | Bhavnagri Veer General Counsel | Option exercise · Stock Option (Right to Buy) | +25,000 | 223,800 | ||
| 2020-10-01 | Amado Rafael EVP of R&D and CMO | Sale | −9,752 | $36.37 | $355K | 128,215 |
| 2020-09-21 | SCHMIDT ERIC THOMAS Chief Financial Officer | Sale | −9,889 | $34.76 | $344K | 1,217,706 |
| 2020-09-21 | SCHMIDT ERIC THOMAS Chief Financial Officer | Sale | −3,200 | $35.96 | $115K | 1,214,506 |
| 2020-09-21 | SCHMIDT ERIC THOMAS Chief Financial Officer | Sale | −1,911 | $37.04 | $71K | 1,212,595 |
| 2020-09-01 | Bhavnagri Veer General Counsel | Option exercise | +25,000 | $2.27 | $57K | 378,902 |
Page 15 of 18 · 348 trades